Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectations

Third-Quarter 2022 Results: -- Net Sales of $925.4 Million -- -- GAAP Net Income of $135.8 Million; Adjusted EBITDA of $335.3 Million, Which Includes $19.0 Million of Acquired IPR&D and Milestones

Related Keywords

United States ,Germany ,Japan ,Austria ,Ireland ,Canada ,Russia ,France ,Ukraine ,Irish ,American ,Geoff Curtis ,Tim Walbert ,Tina Ventura ,Ray Gordon ,Erin Linnihan ,Instagram ,Linkedin ,Twitter ,Companies That Care ,Share Repurchase Program ,Subcutaneous Sc Administration Trial ,American College Of Rheumatology ,Nasdaq ,Key Clinical Development Programs ,Facebook ,Development For The Treatment Of Autoimmune Diseases ,Research In Multiple Sclerosis ,Clinical Program ,Apotex Inc ,Division Of Corporation ,Company Board Of Directors ,Drug Administration ,American Academy Of Ophthalmology ,American Thyroid Association ,Alkem Laboratories Inc ,Exchange Commission ,European Alliance Of Associations ,Brazil National Health Surveillance Agency ,Seramount Best Companies For Dad ,European Committee For Treatment ,Corporate Affairs ,Company Global Expansion ,Which Includes ,Net Sales ,Peak Annual Net Sales Expectations ,Sales Guidance ,Expect Full Year ,Sales Percentage Growth ,Sales Growth Expectations ,Annual Net Sales Expectations ,Company Highlights ,Low Clinical Activity Score ,Thyroid Eye Disease ,Topline Results Expected ,Second Quarter ,Positive Topline Data ,Syndrome Trial ,Patient Enrolled ,Recent Company ,European Alliance ,Syndrome Disease Activity Index ,Syndrome Patient Reported Index ,Pipeline Candidate ,Autoimmune Diseases ,Planned Expansion ,Manufacturing Facility ,Expanded Label ,Include Co Administration ,Biologics License Application ,Dazodalibep Rheumatoid Arthritis ,Key Upcoming Medical Meeting ,American College ,Key Medical Meetings ,American Academy ,Annual Meeting ,Key Medical Meeting ,European Committee ,Multiple Sclerosis ,Global Expansion ,September In October ,Sustainability Accounting Standards Board ,That Care ,Lupus Erythematosus ,Areata Trial ,Planned Phase ,Nephritis Trial ,Arthritis Trial ,Transplant Rejection Trial ,Segmental Glomerulosclerosis ,Cutaneous Systemic Sclerosis Trial ,Pivotal Phase ,Pulmonary Fibrosis Trial ,Gravis Trial ,Related Disease Trial ,Administration Trial ,Cutaneous Systemic Sclerosis Exploratory Trial ,Dermatitis Trial ,Disease Trial ,Infusion Duration Trial ,Dosing Trial ,Patented Medicines Prices Review Board ,Segment Operating ,Alkem Laboratories ,Flow Statement ,Balance Sheet ,Regarding Use ,Consolidated Statements ,Consolidated Balance Sheets ,Cash Flows ,Earnings Per Share ,Per Share ,Per Share Basic ,Operating Cash Flow ,Rate Reconciliation ,Three Months Ended September ,Nine Months Ended September ,Lake Forest ,Corporation Finance ,Vice President ,Investor Relations Officer ,Affairs Chief Communications Officer ,Horizon ,Herapeutics ,Reports ,Third ,Quarter ,022 ,Financial ,Results ,Increases ,Bull ,Ear ,Sales ,Djusted ,Bitda ,Guidance ,Tepezza ,Krystexxa ,Beak ,Nnual ,Expectations ,